Drug intelligence / Profile preview

AK1012

Development stage: Unknown
Lead developer: Anke Bio
Modality: Recombinant Proteins and Enzymes, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

AK1012 is an inhalation solution developed by Anhui Anke Biotechnology (Group) Co., Ltd. It is based on the company's previously listed product, human interferon α 2b injection. The drug is intended for the treatment of lower respiratory tract infections in children caused by respiratory syncytial virus (RSV). Its atomization performance has been studied and it has obtained drug registration approval in China. The highest global R&D status for AK1012 is Phase 1 clinical development[1][3][4].

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on AK1012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK1012.

Explore the full profile